As the main compounds in SL-XM, Xanthinosin inhibits iNOS and COX-2 expression and NF-κB activity by inhibiting LPS-induced degradation of IκBα in microglia (Yoon et al., 2008), and Xanthatin alleviated airway inflammation in asthmatic mice by regulating STAT3/NF-κB signaling pathway (Chang et al., 2020), which partially indicates the anti-RA activity of SL-XM. This evidence concerns the gene NFKBIA and rheumatoid arthritis.